Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Leukotriene Receptor Antagonist and Theophylline in Addition to Inhaled Corticosteroid in Adult Asthma: A Meta-Analysis

  • Fang, Huijuan (Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Wang, Jianmiao (Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Jin, Di (Teaching and Research Division of Internal Medicine, Hubei College of Chinese Medicine) ;
  • Cao, Yong (Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Xu, Yongjian (Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Xiong, Weining (Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology)
  • Received : 2010.09.20
  • Accepted : 2011.01.23
  • Published : 2011.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

This meta-analysis was performed to evaluate the difference of the therapeutic effi cacy and adverse effects of leukotriene receptor antagonist and theophylline added to inhaled corticosteroids in adult asthma. Databases were searched for studies published through Nov, 2010. Randomized-controlled trials containing inhaled corticosteroids plus leukotriene receptor antagonist and inhaled corticosteroids plus sustained-release theophylline for asthma therapy were selected. For each report, data were extracted to the outcomes analyzed: mean change in morning peak expiratory flow, mean change in evening peak expiratory flow, mean change in morning forced expiratory volume in 1 sec, mean change in daily short bete2-agonist use, asthma exacerbation and adverse effects. Four assessable trials including 182 asthmatic patients were identified. Inhaled corticosteroids plus leukotriene receptor antagonist was superior to inhaled corticosteroids plus theophylline therapy in improving morning peak expiratory flow in asthmatics (mean difference 19.08 [95% confidence interval 13.37-23.79] l/min, p<0.001) and morning forced expiratory volume in 1 sec in asthmatics (mean difference 0.09 [95% confidence interval 0.03-0.14] liter, p=0.001). In evening peak expiratory flow, daily short bete2-agonist use, asthma exacerbation and adverse effects, there was no significant difference between these two therapies (All p>0.05). Our meta-analysis showed that the combination of inhaled corticosteroids plus leukotriene receptor antagonist resulted in more improvement in both peak expiratory flow and forced expiratory volume in 1 sec in the morning than inhaled corticosteroids plus sustained-release theophylline in adult asthmatics. Further trials are necessary to evaluate the dominant effects of the former combination.

Keywords

References

  1. Davies, B., Brooks, G. and Devoy, M. (1998) the effi cacy and safety of salmeterol compared to theophylline: Meta-analysis of nine controlled studies. Respir. Med. 92, 256-263. https://doi.org/10.1016/S0954-6111(98)90105-6
  2. Deeks, J. J., Altman, D. and Bradburn, M. J. (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Systematic Reviews in Health Care (M. Egger, G. Davey Smith, D. G. Altman, Eds.), pp. 285-312. BMJ Publishing, Nondon, UK.
  3. Dempsey, O. J., Fowler, S. J., Wilson, A., Kennedy, G. and Lipworth, B. J. (2002) Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 122, 151-159. https://doi.org/10.1378/chest.122.1.151
  4. DerSimonian, R. and Laird, N. (1986) Meta-analysis in clinical trials. Control. Clin. Trials. 7, 177-188. https://doi.org/10.1016/0197-2456(86)90046-2
  5. Ducharme, F. M., Lasserson, T. J. and Cates, C. J. (2006) Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. 18, CD003137.
  6. Evans, D. J., Taylor, D. A., Zetterstrom, O., Chung, K. F., O'Connor, B. J. and Barnes, P. J. (1997) A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N. Engl. J. Med. 337, 1412-1418. https://doi.org/10.1056/NEJM199711133372002
  7. Fanta, C. H. (2009) Asthma. N. Engl. J. Med. 360, 1002-1014. https://doi.org/10.1056/NEJMra0804579
  8. Higgins, J. P., Thompson, S. G., Deeks, J. J. and Altman, D. G. (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557-560. https://doi.org/10.1136/bmj.327.7414.557
  9. Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J., Gavaghan, D. J. and McQuay, H. J. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17, 1-12. https://doi.org/10.1016/0197-2456(95)00134-4
  10. Lipworth, B. J. (1999) Leukotriene-receptor antagonist. Lancet. 353, 57-62. https://doi.org/10.1016/S0140-6736(98)09019-9
  11. Mcivor, R. A., Pizzichini, E., Turner, M. O., Hussack, P., Hargreave, F. E. and Sears, M. R. (1998) Potential masking effects of salmeterol on airway infl ammation in asthma. Am. J. Respir. Crit. Care Med. 158, 924-930. https://doi.org/10.1164/ajrccm.158.3.9802069
  12. Moore, R. H., Khan, A. and Dickey, B. F. (1998) Long-acting inhaled beta2-agonists in asthma therapy. Chest 113, 1095-1108. https://doi.org/10.1378/chest.113.4.1095
  13. National Institutes of Health (NIH). (2002) National heart, lung, and blood institute. global initiative for asthma. NIH Publication, Bethesda, MD.
  14. Orsida, B. E., Ward, C., Li, X., Bish, R., Wilson, J. W., Thien, F. and Walters, E. H. (2001) Effect of a long-acting-beta2-agonist over three months on airway remodeling in asthma. Am. J. Respir. Crit. Care Med. 164, 117-121. https://doi.org/10.1164/ajrccm.164.1.2006003
  15. Price, D. B., Hernandez, D., Magyar, P., Fiterman, J., Beeh, K. M., James, I. G., Konstantopoulos, S., Rojas, R., van Noord, J. A., Pons, M., Gilles, L., Leff, J. A.; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. (2003) Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 58, 211-216. https://doi.org/10.1136/thorax.58.3.211
  16. Schulz, K. F., Chalmers, I., Hayes, R. J. and Altman, D. G. (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 273, 408-412. https://doi.org/10.1001/jama.273.5.408
  17. Shah, A. R., Sharples, L. D., Solanki, R. N. and Shah, K. V. (2006) Double-blind, randomised, controlled trial assessing controller medications in asthma. Respiration. 73, 449-456. https://doi.org/10.1159/000090898
  18. Sindi, A., Todd, D. C. and Nair, P. (2009). Antiinfl ammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and metaanalysis. Chest 136, 145-154. https://doi.org/10.1378/chest.08-2149
  19. Spina, D., Landells, L. J. and Page, C. P. (1998) The role of theophylline and phosphodiesterase 4 isoenzyme inhibitors as anti-infl ammatory drugs. Clin. Exp. Allergy 28(suppl), 24-34.
  20. Tee, A. K., Koh, M. S., Gibson, P. G., Lasserson, T. J., Wilson, A. J. and Irving, L. B. (2007) Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst. Rev. 18, CD001281.
  21. Tsuchida, T., Matsuse, H., Machida, I., Kondo, Y., Saeki, S., Tomari, S., Obase, Y., Matsuo, N., Shimoda, T. and Kohno, S. (2005) Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids. Allergy Asthma. Proc. 26, 287-291.
  22. Vanacker, N. J., Palmans, E., Pauwels, R. A. and Kips, J. C. (2002) Effect of combining salmeterol and fl uticasone on the progress of airway remodeling. Am. J. Respir. Crit. Care Med. 166, 1128-1134. https://doi.org/10.1164/rccm.200203-191OC
  23. Yurdakul, A. S., Calişir, H. C., Tunçtan, B. and Ogretensoy, M. (2002) Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respir. Med. 96, 322-329. https://doi.org/10.1053/rmed.2002.1282